| 摘要 |
The present invention relates to a glucagon-like peptide (GLP) and immunoglobulin hybrid Fc fusion polypeptide. More specifically, the present invention relates to a fusion polypeptide having an excellent effect and having an increased half-life compared to a conventional fusion polypeptide on the basis of the discovery of immunoglobulin hybrid Fc which is suitable to GLP or an analogue thereof; and a pharmaceutical composition for treating diabetes, inflammatory enteric diseases, endoenteritis and diarrhea which are caused by anticancer chemotheraphy, or short-bowel syndromes, wherein the pharmaceutical composition includes the fusion polypeptide of the present invention. The fusion polypeptide of the present invention has an increased half-life compared to conventional GLP-1 or GLP-2 and has excellent resistance against a DPP-4 enzyme, thereby exhibiting an excellent medicinal effect in treating diabetes, inflammatory enteric diseases, endoenteritis and diarrhea which are caused by anticancer chemotheraphy, or short-bowel syndromes compared to a conventional medicine. Accordingly, the fusion polypeptide of the present invention can be usefully applied to medicines and medical products. |
